No more guesswork in drug design—atomic-resolution method exposes what trial and error keep missing

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way, building molecules step by step and observing their behavior at atomic resolution. The science-journalism coverage adds useful context, while the strongest evidential footing still comes from the underlying data, papers or institutional documentation.

It is relevant because cosmology operates at the edge of what current instruments can measure, where systematic errors and model assumptions are never trivial. Small discrepancies between independent measurements have historically pointed toward missing physics rather than simple calibration errors, and the ongoing tension in the Hubble constant is a live example of how a persistent disagreement between methods can reshape the theoretical landscape. Each new dataset that approaches this territory with independent systematics adds real information to a problem that has resisted easy resolution for more than a decade. Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way, building molecules step by step and observing their behavior at atomic resolution.

This approach could significantly speed up the development of new therapies while reducing side effects.

The relevance goes beyond one dataset because even small shifts in measured parameters can matter when the field is testing the limits of the standard cosmological model. The Lambda-CDM framework describes the observable universe with remarkable economy, but its success rests on two components, dark matter and dark energy, whose physical nature remains entirely unknown. Any credible measurement that tightens or loosens the constraints on those components moves the entire theoretical enterprise forward, regardless of whether the immediate result looks dramatic on its own terms.

Because this item comes through Phys. org Chemistry as science journalism, it should be treated as contextual reporting rather than primary evidence. Good science reporting can identify why a result matters, connect it to the wider literature and make technical work readable, but the decisive evidence remains in the original paper, dataset, mission release or technical record. That distinction is especially important when a story is later repeated by aggregators, because repetition increases visibility, not evidential strength.

The next step is to see whether the effect survives when independent surveys, different calibration strategies and tighter control of systematic uncertainties enter the picture. Programmes such as Euclid, DESI and the Rubin Observatory will deliver datasets over the next several years that cover the same parameter space with largely independent methods. If the current signal persists through those tests, its theoretical implications will become impossible to set aside.

Source